Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Polycystic Ovary Syndrome 2Neoplasms 2Diabetes Mellitus, Type 2 2Thyroid Cancer, Papillary 1Solid Cancers 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Liposarcoma 1Leukoplakia, Oral 1Carcinoma, Renal Cell 1Breast Neoplasms 1Alzheimer Disease 1Adenocarcinoma, Follicular 1

Interventions

Doxorubicin 14Radiotherapy 10Ifosfamide 10Trabectedin 7pazopanib 4Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3Chemotherapy, Adjuvant 3temsirolimus 2romidepsin 2ribociclib 2pegfilgrastim 2eribulin 2cixutumumab 2brigimadlin 2belinostat 2Vincristine 2Sunitinib 2Radiotherapy, Conformal 2Gemcitabine 2Epirubicin 2Dexamethasone 2Dactinomycin 2Carboplatin 2soblidotin 1sitravatinib 1siremadlin 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liposarcoma × Rosiglitazone × Clear all
NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
Sarcoma

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡